テキストサイズ

  • テキストサイズ 中
  • テキストサイズ 大

JP

検索

EN

Menu

閉じる

小児科学/小児科学教室

小児科学教室HP https://kpum-ped.com/


大学院科目名
小児科学
医学部教室名 小児科学教室
スタッフ
教授 家原 知子
准教授     秋岡 親司 
客員教授    糸井 利幸、西田 眞佐志、西村 陽
講師      今村 俊彦、土屋 邦彦、大曽根 眞也
講師(併任)  四方 あかね、平井 清、三沢 あき子
助教(学内講師)池田 和幸、森 潤、柳生 茂希、宮地 充
助教(学内講師)(併任)青山 三智子
助教      梶山 葉、河井 容子、長谷川 龍志、戸澤 雄紀、橋口 加名栄、
        吉田 秀樹、瑞木 匡、森元 英周、
        杉本 哲(北部医療センター)、中川 憲夫(北部医療センター)
        富田 晃正(北部医療センター)
        宮垣 知史(北部医療センター)
病院助教    伊藤 育世、井上 聡
助教(特任)  福原 正太、久保 裕
助教(併任)  森元 真梨子、前田 裕史、千原 貴世、阪上 智俊
研究内容
【小児神経部門】
患者由来iPS細胞等を用いた発達性てんかん性脳症の病態解析・新規治療探索。ショウジョウバエモデルを用いた神経発達症の新規治療探索。
 
【小児代謝・内分泌部門】
褐色脂肪細胞・白色脂肪細胞をターゲットにした抗肥満薬の探索、摂食異常の病態解明または摂食中枢を標的とした抗肥満薬の探索、小児肥満におけるバイオマーカーの探索、脂質メディエーターの糖脂質代謝への影響の検証、オフターゲット効果として抗肥満作用を示す既存薬剤の機序解明。
 
【小児腫瘍・血液部門】
神経芽腫、横紋筋肉腫、悪性ラブドイド腫瘍(MRT)など難治性腫瘍に対する病態の解明と治療法の開発、神経芽腫MYCN遺伝子の血清診断、横紋筋肉腫での血清特異的microRNA、遺伝子診断の開発。急性リンパ性および骨髄性白血病の病態解明や新規治療の開発に関する基礎研究。
 
【免疫・膠原病部門】
自己免疫・炎症性疾患に対して分子標的治療法の開発、全国的な特発性付着部炎の研究会の立ち上げに関与し、難病の病態解明。
 
【NICU・新生児部門】
出生体重1500g未満の極低出生体重児の長期予後、 慢性肺疾患の予防に関する研究、NOによる新生児遷延性肺高血圧症の治療、 ディベロップメンタルケアが児の発育に与える影響、 超低出生体重児の急性期の管理法、頭部MRI(拡散強調画像)を用いた早産児の神経発達学的予後の予測、心拍変動解析による新生児のストレス評価、などの臨床研究。
 
【循環器部門】
iPS細胞疾患モデルを用いたガンマグロブリン不応川崎病の病態解明、川崎病発症原因菌としての口腔内バイオフィルム細菌に関する研究、川崎病血管障害と動脈硬化発現に関する研究、川崎病冠動脈瘤を予防するための急性期難治例予測診断キットの開発研究、冠動脈瘤を伴う川崎病患者のレジストリ研究、川崎病感受性遺伝子解析に関する多施設共同研究、小児がん患者の長期フォローアップに基づく薬剤性心毒性のリスク因子の解明、先天性心疾患をもつ思春期・青年期の子どもの心理・発達的特徴に関する研究、先天性心疾患患児における腎機能と心臓カテーテル検査後の腎障害マーカーの推移。
 
【腎臓部門】
腎線維化の進展機序と浸潤マクロファージの役割、およびその治療薬開発などに関するマウス片側尿管結紮モデルを用いた研究。腎障害に対する尿中/血中バイオマーカーに関する臨床研究。
研究業績
  1. Okamoto K, Imamura T, Tanaka S, Urata T, Yoshida H, Shiba N, Iehara T. The Nup98::Nsd1 fusion gene induces CD123 expression in 32D cells.Int J Hematol. 2023 May 13. doi: 10.1007/s12185-023-03612-z.
  2. Yamaguchi M, Mori J, Nishida N, Miyagaki S, Kawabe Y, Ota T, Morimoto H, Tsuma Y, Fukuhara S, Ogata T, Okamaura T, Nakanishi N, Hamaguchi M, Nakajima H, Fukui M, Iehara T. High-fat diet during pregnancy lowers fetal weight and has a long-lasting adverse effect on brown adipose tissue in the offspring. J Dev Orig Health Dis. 2023 Apr;14(2):261-271.
  3. Shoji C, Kikuchi K, Yoshida H, Miyachi M, Yagyu S, Tsuchiya K, Nakaya T, Hosoi H, Iehara T. In ovo chorioallantoic membrane assay as a xenograft model for pediatric rhabdomyosarcoma. Oncol Rep. 2023 Apr;49(4):76. doi: 10.3892/or.2023.8513.
  4. Ota T, Mori J, Kawabe Y, Morimoto H, Fukuhara S, Kodo K, Sugimoto S, Kosaka K, Nakajima H, Hosoi H. Association of Type 2 Deiodinase Thr92Ala Polymorphism with Pediatric Obesity in Japanese Children: A Case-Control Study. Children (Basel). 2022 Sep 20;9(10):1421.
  5. Mayumi A, Tomii T, Kanayama T, Mikami T, Tanaka K, Ueno H, Yoshida H, Kato I, Kawamura M, Nakahata T, Takita J, Hosoi H, Imamura T. The combination of ruxolitinib and Bcl-2/Mcl-1 inhibitors has a synergistic effect on leukemic cells carrying a SPAG9::JAK2 fusion. Cancer Gene Ther. 2022 Jul 25. doi: 10.1038/s41417-022-00511-z.
  6. Kaneda D, Iehara T, Kikuchi K, Sugimoto Y, Nakagawa N, Yagyu S, Miyachi M, Konishi E, Sakai T, Hosoi H. The histone deacetylase inhibitor OBP-801 has in vitro/in vivo anti-neuroblastoma activity. Pediatr Int. 2022 Jan;64(1):e15159. doi: 10.1111/ped.15159.
  7. Suematsu M, Yagyu S, Nagao N, Kubota S, Shimizu Y, Tanaka M, Nakazawa Y, Imamura T. PiggyBac Transposon-Mediated CD19 Chimeric Antigen Receptor-T Cells Derived From CD45RA-Positive Peripheral Blood Mononuclear Cells Possess Potent and Sustained Antileukemic Function. Front Immunol. 2022 Jan 27;13:770132. doi: 10.3389/fimmu.2022.770132. eCollection 2022
  8. Ichise E, Chiyonobu T, Ishikawa M,Tanaka Y, Shibata M, Tozawa T, Taura Y,Yamashita S,Yoshida M, Morimoto M, Higurashi N, Yamamoto T, Okano H,Hirose S. Impaired neuronal activity and differential gene expression in STXBP1 encephalopathy patient iPSC-derived GABAergic neurons. Hum Mol Genet 26;30(14):1337-1348, 2021.
  9. Miyagaki S, Kikuchi K,Mori J,Lopaschuk GD, Iehara T, Hosoi H. Inhibition of lipid metabolism exerts antitumor effects on rhabdomyosarcoma. Cancer Med. 2021 Sep;10(18):6442-6455.
  10. Tomida A, Yagyu S, Nakamura K, Kubo H, Yamashima K, Nakazawa Y, Hosoi H, Iehara T.Inhibition of MEK pathway enhances the antitumor efficacy of chimeric antigen receptor T cells against neuroblastoma. Cancer Sci 2021; 112: 4026-4036.
  11. Kubo H, Yagyu S, Nakamura K, Yamashima K, Tomida A, Kikuchi K, Iehara T, Nakazawa Y, Hosoi H. Development of non-viral, ligand-dependent, EPHB4-specific chimeric antigen receptor T cells for treatment of rhabdomyosarcoma. Mol Ther Oncolytics 2021; 20: 646-658.
  12. Sakaue S, Hasegawa T, Sakai K, Zen Y, Tozawa T, Chiyonobu T, Yamada K, Morimoto M, Hosoi H. Low-grade IVH in preterm infants causes cerebellar damage,motor,and cognitive impairment. Pediatr Int 2021 Mar 11. doi: 10.1111/ped.14691.
  13. Tomii T, Imamura T, Tanaka K, Kato I, Mayumi A, Soma E, Yano M, Sakamoto K, Mikami T, Morita M, Kiyokawa N, Horibe K, Adachi S, Nakahata T, Takita J, Hosoi H. Leukemic cells expressing NCOR1-LYN are sensitive to dasatinib in vivo in a patient-derived xenograft mouse model. Leukemia 2020 Nov 16. doi: 10.1038/s41375-020-01091-3.
  14. Takai A, Chiyonobu T, Ueoka I, Tanaka R, Tozawa T, Yoshida H, Morimoto M, Hosoi H, Yamaguchi M. A novel Drosophila model for neurodevelopmental disorders associated with Shwachman-Diamond syndrome. Neurosci Lett 2020 Nov 20;739:135449. doi: 10.1016/j.neulet.2020.135449.
  15. Kuwahara Y, Iehara T, Ichise E, Katsumi Y, Ouchi K, Tsuchiya K, Miyachi M, Konishi E, Sasajima H, Nakamura S, Fumino S, Tajiri T, Johann PD, FrÜhwald MC, Yoshida T, Okuda T, Hosoi H. Novel two MRT cell lines established from multiple sites of a synchronous MRT patient. Anticancer Res 2020; 40: 6159-6170.
  16. Sugimoto Y, Katsumi Y, Iehara T, Kaneda D, Tomoyasu C, Ouchi K, Yoshida H, Miyachi M, Yagyu S, Kikuchi K, Tsuchiya K, Kuwahara Y, Sakai T, Hosoi H. The novel histone deacetylase inhibitor, OBP-801, induces apoptosis in rhabdoid tumors by releasing the silencing of NOXA. Mol Cancer Ther 2020; 19: 1992-2000.
  17. Kanayama T, Imamura T, Mayumi A, Soma E, Sakamoto K, Hayakawa F, Tanizawa A, Kiyokawa N, Hosoi H. Functional analysis of a novel fusion protein PAX5-KIDINS220 identified in a pediatric Ph-like ALL patient. Int J Hematol 2020; 112: 714-719.
  18. Iehara T, Manabe A, Hosoi H. Statement on the prevention and treatment of COVID-19 in patients with pediatric cancer in Japan. Pediatr Blood Cancer 2020 Sep;67(9):e28440. doi: 10.1002/pbc.28440.
  19. Ouchi K, Miyachi M, Yagyu S, Kikuchi K, Kuwahara Y, Tsuchiya K, Iehara T, Hosoi H.Oncogenic role of HMGA2 in fusion-negative rhabdomyosarcoma cells. Cancer Cell Int 2020 May 24;20:192. doi: 10.1186/s12935-020-01282-z.
  20. Hasegawa D, Imamura T, Yumura-Yagi K, Takahashi Y, Usami I, Suenobu SI, Nishimura S, Suzuki N, Hashii Y, Deguchi T, Moriya-Saito A, Kato K, Kosaka Y, Hirayama M, Iguchi A, Kawasaki H, Hori H, Sato A, Kudoh T, Nakahata T, Oda M, Hara J, Horibe K. Risk-adjusted therapy for pediatric non-t cell all improves outcomes for standard risk patients: results of JACLS ALL-02. Blood Cancer J 2020 Feb 27;10(2):23. doi: 10.1038/s41408-020-0287-4.
  21. Hashiguchi K, Kuriyama N, Koyama T, Matsui D, Ozaki E, Hasegawa T, Tokuda S, Niwa F, Iwasa K, Watanabe I, Teramukai S, Kitawaki J, Watanabe Y, Uehara R, Hosoi H. Validity of stress assessment using heart-rate variability in newborns. Pediatr Int 2020-;62:694-700.
  22. Kawabe Y, Mori J, Morimoto H, Yamaguchi M, Miyagaki S, Ota T, Tsuma Y, Fukuhara S, Nakajima H, Oudit GY, Hosoi H. ACE2 exerts anti-obesity effect via stimulating brown adipose tissue and induction of browning in white adipose tissue. Am J Physiol Endocrinol Metab 2019; 317: E1140-E1149.
  23. Sakamoto K, Shiba N, Deguchi T, Kiyokawa N, Hashii Y, Moriya-Saito A, Tomizawa D, Taga T, Adachi S, Horibe K, Imamura T. Negative CD19 expression is associated with inferior relapse-free survival in children with RUNX1-RUNX1T1-positive acute myeloid leukaemia: results from the Japanese Paediatric Leukaemia/Lymphoma Study Group AML-05 Study. Br J Haematol 2019; 187: 372-376.
  24. Osone S, Fukushima K, Yano M, Kakazu M, Sano H, Kato Y, Shinkoda Y, Shinoda K, Mori N, Adachi S. Supportive care for hemostatic complications associated with pediatric leukemia: a national survey in Japan. Int J Hematol 2019; 110: 743-750.
  25. Nishida M, Kubo S, Morishita Y, Nishikawa K, Ikeda K, Itoi T, Hosoi H. Kidney injury biomarkers after cardiac angiography in children with congenital heart disease. Congenit Heart Dis 2019; 14: 1087-1093.
  26. Iehara T, Yagyu S, Gotoh T, Ouchi K, Yoshida H, Miyachi M, Kikuchi K, Sugimoto T, Hosoi H. A prospective evaluation of liquid biopsy for detecting MYCN amplification in neuroblastoma patients. Jpn J Clin Oncol 2019; 49: 743-748.
  27. Iehara T, Yoneda A, Yokota I, Takahashi H, Teramukai S, Kamijyo T, Nakazawa A, Takimoto T, Kikuta A, Yagyu S, Ikeda H, Nakagawara A, Tajiri T. Results of a prospective clinical trial JN-L-10 using image-defined risk factors to inform surgical decisions for children with low-risk neuroblastoma disease: a report from the Japan Children's Cancer Group Neuroblastoma Committee. Pediatr Blood Cancer 2019; Nov;66(11):e27914.doi: 10.1002/pbc.27914.
  28. Akioka S. Interleukin-6 in juvenile idiopathic arthritis. Mod Rheumatol 2019; 29: 275-286.
  29. Zen Y, Chiyonobu T, Yuge M, Yokota I, Morimoto M, Teramukai S, Hosoi H. Gender differences in occurrence of behavioral and emotional problems at the lower grades of elementary school: association with developmental and behavioral characteristics at 5 years. Brain Dev 2019; 41: 760-768.
  30. Nakamura A, Ikeda K, Hamaoka K. Aetiological significance of infectious stimuli in Kawasaki Disease. Front Pediatr 2019 Jun 28;7:244. doi: 10.3389/fped.2019.00244.
  31. Nakagawa N, Kikuchi K, Yagyu S, Miyachi M, Iehara T, Tajiri T, Sakai T, Hosoi H. Mutations in the RAS pathway as potential precision medicine targets in treatment of rhabdomyosarcoma. Biochem Biophys Res Commun 2019; 512: 524-530.
  32. Fukuhara S, Nakajima H, Sugimoto S, Kodo K, Shigehara K, Morimoto H, Tsuma Y, Moroto M, Mori J, Kosaka K, Morimoto M, Hosoi H. High-fat diet accelerates extreme obesity with hyperphagia in female heterozygous Mecp2-null mice. PLoS One 2019 Jan 4;14(1):e0210184. doi: 10.1371/journal.pone.0210184.
  33. Tsuma Y, Mori J, Ota T, Kawabe Y, Morimoto H, Fukuhara S, Kodo K, Umemura A, Nakajima H, Hosoi H. Erythropoietin and long-acting erythropoiesis stimulating agent ameliorate non-alcoholic fatty liver disease by increasing lipolysis and decreasing lipogenesis via EPOR/STAT pathway. Biochem Biophys Res Commun 2019; 509: 306-313.
  34. Tomoyasu C, Kikuchi K, Kaneda D, Yagyu S, Miyachi M, Tsuchiya K, Iehara T, Sakai T, Hosoi H. OBP‑801, a novel histone deacetylase inhibitor, induces m‑phase arrest and apoptosis in rhabdomyosarcoma cells. Oncol Rep 2019; 41: 643-649.
問い合わせ先
教室独自のHP

〒602-8566. 京都市上京区河原町通広小路上る梶井町465

お問い合わせ先
TEL:075-251-5111
FAX:075-211-7093